Please assess the completion status of the following clinical trial:

Trial Title: Medical Management of Late Intrauterine Death.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Closed cervix without evidence of cervical dilation or baseline uterine activity.~* A Bishop score of \<5, having intact membranes.~* Gestation greater than or equal to 20 weeks established by the date of menstruation or by fetometry and ultrasound-confirmed late IUFD.~Exclusion Criteria:~* Multiple pregnancies.~* IUFD after late foeticide or the management of specific medical conditions associated with an increase in the risk of IUFD.~* Patients with a history of hypertension.~* Women with a history of unexplained antepartum haemorrhage, pelvic dystocia or any another counter-indications where medications were used.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- isosorbide dinitrate-oxytocin (Type: EXPERIMENTAL): Preinduction with isosorbide dinitrate gel solution (80 mg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.~If the cervical conditions (\<7 Bishop Score) did not change after the treatment application, a new dose, without exceeding 4 doses, to facilitate cervical ripening.
- misoprostol-oxytocin (Type: PLACEBO_COMPARATOR): Preinduction with misoprostol gel solution (100 mcg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.~If the cervical conditions (\<7 Bishop score) did not change after the treatment application, participants received a new dose, without exceeding 4 doses, to facilitate cervical ripening.

Based on this trial design, predict the completion outcome and termination type (if applicable).